Phathom Responds To BDR Lawsuit Against FDA Over Voquezna ANDA, Says FDA Correctly Recognized NCE Exclusivity Through May 3, 2032
Share
Why It Matters
Phathom says the FDA correctly protected its medicine from copies. The company has legal protection until 2032 for this drug.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.